INDV Stock Price | Indivior PLC Ordinary Shares P/E, Revenue, EPS, & Forecasts

Indivior PLC Ordinary Shares • INDV

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Indivior PLC Ordinary Shares

Ticker

INDV

Trading on

NASDAQ

ISIN

GB00BN4HT335

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

CEO

Joseph J. Ciaffoni

Headquarters

10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235

Employees

1,030

Website

indivior.com

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Metrics

BasicAdvanced

Market cap

$1.71B

P/E ratio

EPS

-$0.05

Dividend Yield

0.00%

Beta

0.25

Forward P/E ratio

EBIDTA

$309M

Ex dividend date

2016-06-16

Price & volume

Market cap

$1.71B

Average daily volume

1.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

1.47

Price to book

145.25

Earnings

EPS

-$0.05

EPS estimate (current quarter)

$0.23

EPS estimate (next quarter)

$0.26

EBITDA

$309M

Revenues (TTM)

$1.17B

Revenues per share (TTM)

$9.05

Technicals

Beta

0.25

52-week High

$16.98

52-week Low

$7.33

50-day moving average

$11.01

200-day moving average

$10.59

Short ratio

2.56

Short %

1.81%

Management effectiveness

ROE (TTM)

12.20%

ROA (TTM)

12.60%

Profit margin

-5.30%

Gross profit margin

$955M

Operating margin

25.56%

Growth

Quarterly earnings growth (YoY)

-15.50%

Quarterly revenue growth (YoY)

-6.30%

Share stats

Outstanding Shares

125M

Float

89.7M

Insiders %

4.01%

Institutions %

88.98%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$14.67

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.79

$0.40

-297.50%

Q2 • 24Missed

$0.03

$0.31

-90.32%

Q3 • 24Missed

$0.32

$0.26

22.65%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$299M

$59M

19.73%

Q4 • 24

$266M

$47M

17.67%

Q1 • 25

-11.04%

-20.34%

-10.46%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$1.32B

$1.67B

126.38%

Q4 • 24

$1.38B

$1.66B

120.80%

Q1 • 25

4.25%

-0.36%

-4.42%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-5M

$10M

$27M

$-21M

Q4 • 24

$75M

$-5M

$-17M

$70M

Q1 • 25

-1,600.00%

-150.00%

-162.96%

-433.33%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Indivior PLC Ordinary Shares share?

Indivior PLC Ordinary Shares shares are currently traded for undefined per share.

How many shares does Indivior PLC Ordinary Shares have?

Indivior PLC Ordinary Shares currently has 125M shares.

Does Indivior PLC Ordinary Shares pay dividends?

No, Indivior PLC Ordinary Shares doesn't pay dividends.

What is Indivior PLC Ordinary Shares 52 week high?

Indivior PLC Ordinary Shares 52 week high is $16.98.

What is Indivior PLC Ordinary Shares 52 week low?

Indivior PLC Ordinary Shares 52 week low is $7.33.

What is the 200-day moving average of Indivior PLC Ordinary Shares?

Indivior PLC Ordinary Shares 200-day moving average is $10.59.

Who is Indivior PLC Ordinary Shares CEO?

The CEO of Indivior PLC Ordinary Shares is Joseph J. Ciaffoni.

How many employees Indivior PLC Ordinary Shares has?

Indivior PLC Ordinary Shares has 1,030 employees.

What is the market cap of Indivior PLC Ordinary Shares?

The market cap of Indivior PLC Ordinary Shares is $1.71B.

What is the P/E of Indivior PLC Ordinary Shares?

The current P/E of Indivior PLC Ordinary Shares is null.

What is the EPS of Indivior PLC Ordinary Shares?

The EPS of Indivior PLC Ordinary Shares is -$0.05.

What is the PEG Ratio of Indivior PLC Ordinary Shares?

The PEG Ratio of Indivior PLC Ordinary Shares is null.

What do analysts say about Indivior PLC Ordinary Shares?

According to the analysts Indivior PLC Ordinary Shares is considered a buy.